Inflammatory mediators from AT, such as leptin, adiponectin, TNF-α, and IL-6, offer promising biomarkers for risk stratification, disease monitoring, and precision therapies targeting adipokine pathways or host modulation. This evidence concerns the gene ADIPOQ and ataxia telangiectasia.